Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9MKD

Crystal structure of MALT1 in complex with an allosteric inhibitor

This is a non-PDB format compatible entry.
Summary for 9MKD
Entry DOI10.2210/pdb9mkd/pdb
DescriptorMucosa-associated lymphoid tissue lymphoma translocation protein 1, CALCIUM ION, TRIETHYLENE GLYCOL, ... (5 entities in total)
Functional Keywordsallosteric inhibitor, hydrolase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight89024.17
Authors
Bell, J.A. (deposition date: 2024-12-17, release date: 2025-10-29)
Primary citationNie, Z.,Trzoss, M.,Placzek, A.T.,Trzoss, L.,Krilov, G.,Feng, S.,Lawrenz, M.,Ye, M.,Marshall, N.,Dingley, K.H.,Pelletier, R.D.,Lai, W.G.,Bell, J.A.,Tang, H.,Devine, P.,Liu, Z.,Skrdla, P.,Shimanovich, R.,Liu, M.,Wang, R.,Xu, X.,Abel, R.,Akinsanya, K.,Yin, W.
Accelerated In Silico Discovery of SGR-1505 : A Potent MALT1 Allosteric Inhibitor for the Treatment of Mature B-Cell Malignancies.
J.Med.Chem., 2025
Cited by
PubMed Abstract: MALT1 is a key component of the CARD11-BCL10-MALT1 (CBM) complex downstream from BTK on the B-cell receptor signaling pathway. It is a key mediator of NF-κB signaling and considered a potential therapeutic target for several subtypes of non-Hodgkin's B-cell lymphomas. By applying advanced physics-based modeling techniques, including combining free energy calculations with machine learning methods and a chemistry-aware compound enumeration workflow, extensive sets of design ideas were explored to quickly identify a novel hit series. Multiparameter optimization allowed efficient prioritization of molecules with good potency and drug-like properties during lead optimization, which led to the discovery of a highly potent MALT1 inhibitor, , with a well-balanced property profile. It demonstrated strong antitumor activity alone and in combination with BTK inhibitor in multiple B-cell lymphoma xenograft models and progressed to a phase 1 clinical trial in patients with mature B-cell neoplasms.
PubMed: 41078320
DOI: 10.1021/acs.jmedchem.5c01494
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.45 Å)
Structure validation

243911

数据于2025-10-29公开中

PDB statisticsPDBj update infoContact PDBjnumon